Time Course of Treatment Effect of OROS® Methylphenidate in Children With ADHD
Objective: The authors evaluated the time course of the treatment effect of Osmotic-Release Oral System methylphenidate (OROS® MPH) HCl (Concerta®, Raritan, NJ) CII in children with ADHD. Method: Data were combined from two double-blind, randomized, placebo-controlled, cross-over, analog classroom s...
Gespeichert in:
| Veröffentlicht in: | Journal of attention disorders 2012-11, Vol.16 (8), p.697-705 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 705 |
|---|---|
| container_issue | 8 |
| container_start_page | 697 |
| container_title | Journal of attention disorders |
| container_volume | 16 |
| creator | Armstrong, Robert B. Damaraju, CV Ascher, Steve Schwarzman, Lesley O’Neill, James Starr, H. Lynn |
| description | Objective: The authors evaluated the time course of the treatment effect of Osmotic-Release Oral System methylphenidate (OROS® MPH) HCl (Concerta®, Raritan, NJ) CII in children with ADHD. Method: Data were combined from two double-blind, randomized, placebo-controlled, cross-over, analog classroom studies in children (9-12 years) with ADHD. Participants received an individualized dose of placebo or OROS® MPH on two laboratory school days. Permanent Product Math Test and Swanson, Kotkin, Agler, M-Flynn, and Pelham scores were evaluated 0.5 hr before dosing and 1, 2, 4, 10, 11, and 12.5 hr post dose. Analysis used a repeated-measures mixed model. Results: Treatment effects were present at all postdose assessment points (p < .0001 for all comparisons, n = 139). Adverse events were similar to previous reports for OROS® MPH. Conclusion: A robust treatment effect occurred with OROS® MPH; onset was at 1 hr and persisted for at least 12.5 hr after dosing. |
| doi_str_mv | 10.1177/1087054711425772 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1093513942</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ericid>EJ991623</ericid><sage_id>10.1177_1087054711425772</sage_id><sourcerecordid>1093513942</sourcerecordid><originalsourceid>FETCH-LOGICAL-c358t-c31d8f1c785dc727b533527271107b2385588d43a4ccfe226bc9c4721b0f61e33</originalsourceid><addsrcrecordid>eNp1kD1PwzAQhi0EglLYGRDyyBLw-aN2xqotFASqBEWMUeJcaFA-ip0O_VP8CH4ZrloYkFjsk9_n7qyHkDNgVwBaXwMzmimpASRXWvM90gOldARcDvZDHeJokx-RY-_fGRM6QIfkiHNmpJSmR2bzskY6alfOI20LOneYdjU2HZ0UBdpu8zZ7mj1_fdJH7BbrarnApszTDmnZ0NGirHKHDX0tuwUdjqfjE3JQpJXH093dJy83k_loGj3Mbu9Gw4fICmW6cEJuCrDaqNxqrjMlhOKhAGA648IoZUwuRSqtLZDzQWZjKzWHjBUDQCH65HI7d-najxX6LqlLb7Gq0gbblU-AxUKBiCUPKNui1rXeOyySpSvr1K0DlGw0Jn81hpaL3fRVVmP-2_DjLQDnWwBdaX_jyX0cw4BvfhdtY5--YfIe7DZBxv_7vgGylIDm</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1093513942</pqid></control><display><type>article</type><title>Time Course of Treatment Effect of OROS® Methylphenidate in Children With ADHD</title><source>MEDLINE</source><source>SAGE Complete A-Z List</source><creator>Armstrong, Robert B. ; Damaraju, CV ; Ascher, Steve ; Schwarzman, Lesley ; O’Neill, James ; Starr, H. Lynn</creator><creatorcontrib>Armstrong, Robert B. ; Damaraju, CV ; Ascher, Steve ; Schwarzman, Lesley ; O’Neill, James ; Starr, H. Lynn</creatorcontrib><description>Objective: The authors evaluated the time course of the treatment effect of Osmotic-Release Oral System methylphenidate (OROS® MPH) HCl (Concerta®, Raritan, NJ) CII in children with ADHD. Method: Data were combined from two double-blind, randomized, placebo-controlled, cross-over, analog classroom studies in children (9-12 years) with ADHD. Participants received an individualized dose of placebo or OROS® MPH on two laboratory school days. Permanent Product Math Test and Swanson, Kotkin, Agler, M-Flynn, and Pelham scores were evaluated 0.5 hr before dosing and 1, 2, 4, 10, 11, and 12.5 hr post dose. Analysis used a repeated-measures mixed model. Results: Treatment effects were present at all postdose assessment points (p < .0001 for all comparisons, n = 139). Adverse events were similar to previous reports for OROS® MPH. Conclusion: A robust treatment effect occurred with OROS® MPH; onset was at 1 hr and persisted for at least 12.5 hr after dosing.</description><identifier>ISSN: 1087-0547</identifier><identifier>EISSN: 1557-1246</identifier><identifier>DOI: 10.1177/1087054711425772</identifier><identifier>PMID: 22084448</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Administration, Oral ; Attention ; Attention Deficit Disorder with Hyperactivity - drug therapy ; Attention Deficit Hyperactivity Disorder ; Central Nervous System Stimulants - administration & dosage ; Central Nervous System Stimulants - therapeutic use ; Child ; Children ; Cross-Over Studies ; Delayed-Action Preparations ; Dose-Response Relationship, Drug ; Double-Blind Method ; Drug Administration Schedule ; Drug Therapy ; Female ; Humans ; Laboratory Schools ; Male ; Mathematics Tests ; Measures (Individuals) ; Methylphenidate - administration & dosage ; Methylphenidate - therapeutic use ; Participant Characteristics ; Schools ; Scores ; Statistical Analysis ; Treatment Outcome</subject><ispartof>Journal of attention disorders, 2012-11, Vol.16 (8), p.697-705</ispartof><rights>2012 SAGE Publications</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c358t-c31d8f1c785dc727b533527271107b2385588d43a4ccfe226bc9c4721b0f61e33</citedby><cites>FETCH-LOGICAL-c358t-c31d8f1c785dc727b533527271107b2385588d43a4ccfe226bc9c4721b0f61e33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/1087054711425772$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/1087054711425772$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,21799,27903,27904,43600,43601</link.rule.ids><backlink>$$Uhttp://eric.ed.gov/ERICWebPortal/detail?accno=EJ991623$$DView record in ERIC$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22084448$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Armstrong, Robert B.</creatorcontrib><creatorcontrib>Damaraju, CV</creatorcontrib><creatorcontrib>Ascher, Steve</creatorcontrib><creatorcontrib>Schwarzman, Lesley</creatorcontrib><creatorcontrib>O’Neill, James</creatorcontrib><creatorcontrib>Starr, H. Lynn</creatorcontrib><title>Time Course of Treatment Effect of OROS® Methylphenidate in Children With ADHD</title><title>Journal of attention disorders</title><addtitle>J Atten Disord</addtitle><description>Objective: The authors evaluated the time course of the treatment effect of Osmotic-Release Oral System methylphenidate (OROS® MPH) HCl (Concerta®, Raritan, NJ) CII in children with ADHD. Method: Data were combined from two double-blind, randomized, placebo-controlled, cross-over, analog classroom studies in children (9-12 years) with ADHD. Participants received an individualized dose of placebo or OROS® MPH on two laboratory school days. Permanent Product Math Test and Swanson, Kotkin, Agler, M-Flynn, and Pelham scores were evaluated 0.5 hr before dosing and 1, 2, 4, 10, 11, and 12.5 hr post dose. Analysis used a repeated-measures mixed model. Results: Treatment effects were present at all postdose assessment points (p < .0001 for all comparisons, n = 139). Adverse events were similar to previous reports for OROS® MPH. Conclusion: A robust treatment effect occurred with OROS® MPH; onset was at 1 hr and persisted for at least 12.5 hr after dosing.</description><subject>Administration, Oral</subject><subject>Attention</subject><subject>Attention Deficit Disorder with Hyperactivity - drug therapy</subject><subject>Attention Deficit Hyperactivity Disorder</subject><subject>Central Nervous System Stimulants - administration & dosage</subject><subject>Central Nervous System Stimulants - therapeutic use</subject><subject>Child</subject><subject>Children</subject><subject>Cross-Over Studies</subject><subject>Delayed-Action Preparations</subject><subject>Dose-Response Relationship, Drug</subject><subject>Double-Blind Method</subject><subject>Drug Administration Schedule</subject><subject>Drug Therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Laboratory Schools</subject><subject>Male</subject><subject>Mathematics Tests</subject><subject>Measures (Individuals)</subject><subject>Methylphenidate - administration & dosage</subject><subject>Methylphenidate - therapeutic use</subject><subject>Participant Characteristics</subject><subject>Schools</subject><subject>Scores</subject><subject>Statistical Analysis</subject><subject>Treatment Outcome</subject><issn>1087-0547</issn><issn>1557-1246</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kD1PwzAQhi0EglLYGRDyyBLw-aN2xqotFASqBEWMUeJcaFA-ip0O_VP8CH4ZrloYkFjsk9_n7qyHkDNgVwBaXwMzmimpASRXWvM90gOldARcDvZDHeJokx-RY-_fGRM6QIfkiHNmpJSmR2bzskY6alfOI20LOneYdjU2HZ0UBdpu8zZ7mj1_fdJH7BbrarnApszTDmnZ0NGirHKHDX0tuwUdjqfjE3JQpJXH093dJy83k_loGj3Mbu9Gw4fICmW6cEJuCrDaqNxqrjMlhOKhAGA648IoZUwuRSqtLZDzQWZjKzWHjBUDQCH65HI7d-najxX6LqlLb7Gq0gbblU-AxUKBiCUPKNui1rXeOyySpSvr1K0DlGw0Jn81hpaL3fRVVmP-2_DjLQDnWwBdaX_jyX0cw4BvfhdtY5--YfIe7DZBxv_7vgGylIDm</recordid><startdate>201211</startdate><enddate>201211</enddate><creator>Armstrong, Robert B.</creator><creator>Damaraju, CV</creator><creator>Ascher, Steve</creator><creator>Schwarzman, Lesley</creator><creator>O’Neill, James</creator><creator>Starr, H. Lynn</creator><general>SAGE Publications</general><scope>7SW</scope><scope>BJH</scope><scope>BNH</scope><scope>BNI</scope><scope>BNJ</scope><scope>BNO</scope><scope>ERI</scope><scope>PET</scope><scope>REK</scope><scope>WWN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201211</creationdate><title>Time Course of Treatment Effect of OROS® Methylphenidate in Children With ADHD</title><author>Armstrong, Robert B. ; Damaraju, CV ; Ascher, Steve ; Schwarzman, Lesley ; O’Neill, James ; Starr, H. Lynn</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c358t-c31d8f1c785dc727b533527271107b2385588d43a4ccfe226bc9c4721b0f61e33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Administration, Oral</topic><topic>Attention</topic><topic>Attention Deficit Disorder with Hyperactivity - drug therapy</topic><topic>Attention Deficit Hyperactivity Disorder</topic><topic>Central Nervous System Stimulants - administration & dosage</topic><topic>Central Nervous System Stimulants - therapeutic use</topic><topic>Child</topic><topic>Children</topic><topic>Cross-Over Studies</topic><topic>Delayed-Action Preparations</topic><topic>Dose-Response Relationship, Drug</topic><topic>Double-Blind Method</topic><topic>Drug Administration Schedule</topic><topic>Drug Therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Laboratory Schools</topic><topic>Male</topic><topic>Mathematics Tests</topic><topic>Measures (Individuals)</topic><topic>Methylphenidate - administration & dosage</topic><topic>Methylphenidate - therapeutic use</topic><topic>Participant Characteristics</topic><topic>Schools</topic><topic>Scores</topic><topic>Statistical Analysis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Armstrong, Robert B.</creatorcontrib><creatorcontrib>Damaraju, CV</creatorcontrib><creatorcontrib>Ascher, Steve</creatorcontrib><creatorcontrib>Schwarzman, Lesley</creatorcontrib><creatorcontrib>O’Neill, James</creatorcontrib><creatorcontrib>Starr, H. Lynn</creatorcontrib><collection>ERIC</collection><collection>ERIC (Ovid)</collection><collection>ERIC</collection><collection>ERIC</collection><collection>ERIC (Legacy Platform)</collection><collection>ERIC( SilverPlatter )</collection><collection>ERIC</collection><collection>ERIC PlusText (Legacy Platform)</collection><collection>Education Resources Information Center (ERIC)</collection><collection>ERIC</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of attention disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Armstrong, Robert B.</au><au>Damaraju, CV</au><au>Ascher, Steve</au><au>Schwarzman, Lesley</au><au>O’Neill, James</au><au>Starr, H. Lynn</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><ericid>EJ991623</ericid><atitle>Time Course of Treatment Effect of OROS® Methylphenidate in Children With ADHD</atitle><jtitle>Journal of attention disorders</jtitle><addtitle>J Atten Disord</addtitle><date>2012-11</date><risdate>2012</risdate><volume>16</volume><issue>8</issue><spage>697</spage><epage>705</epage><pages>697-705</pages><issn>1087-0547</issn><eissn>1557-1246</eissn><abstract>Objective: The authors evaluated the time course of the treatment effect of Osmotic-Release Oral System methylphenidate (OROS® MPH) HCl (Concerta®, Raritan, NJ) CII in children with ADHD. Method: Data were combined from two double-blind, randomized, placebo-controlled, cross-over, analog classroom studies in children (9-12 years) with ADHD. Participants received an individualized dose of placebo or OROS® MPH on two laboratory school days. Permanent Product Math Test and Swanson, Kotkin, Agler, M-Flynn, and Pelham scores were evaluated 0.5 hr before dosing and 1, 2, 4, 10, 11, and 12.5 hr post dose. Analysis used a repeated-measures mixed model. Results: Treatment effects were present at all postdose assessment points (p < .0001 for all comparisons, n = 139). Adverse events were similar to previous reports for OROS® MPH. Conclusion: A robust treatment effect occurred with OROS® MPH; onset was at 1 hr and persisted for at least 12.5 hr after dosing.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>22084448</pmid><doi>10.1177/1087054711425772</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1087-0547 |
| ispartof | Journal of attention disorders, 2012-11, Vol.16 (8), p.697-705 |
| issn | 1087-0547 1557-1246 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1093513942 |
| source | MEDLINE; SAGE Complete A-Z List |
| subjects | Administration, Oral Attention Attention Deficit Disorder with Hyperactivity - drug therapy Attention Deficit Hyperactivity Disorder Central Nervous System Stimulants - administration & dosage Central Nervous System Stimulants - therapeutic use Child Children Cross-Over Studies Delayed-Action Preparations Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Drug Therapy Female Humans Laboratory Schools Male Mathematics Tests Measures (Individuals) Methylphenidate - administration & dosage Methylphenidate - therapeutic use Participant Characteristics Schools Scores Statistical Analysis Treatment Outcome |
| title | Time Course of Treatment Effect of OROS® Methylphenidate in Children With ADHD |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T04%3A34%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Time%20Course%20of%20Treatment%20Effect%20of%20OROS%C2%AE%20Methylphenidate%20in%20Children%20With%20ADHD&rft.jtitle=Journal%20of%20attention%20disorders&rft.au=Armstrong,%20Robert%20B.&rft.date=2012-11&rft.volume=16&rft.issue=8&rft.spage=697&rft.epage=705&rft.pages=697-705&rft.issn=1087-0547&rft.eissn=1557-1246&rft_id=info:doi/10.1177/1087054711425772&rft_dat=%3Cproquest_cross%3E1093513942%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1093513942&rft_id=info:pmid/22084448&rft_ericid=EJ991623&rft_sage_id=10.1177_1087054711425772&rfr_iscdi=true |